Compare Incyte Corporation (INCY) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Trade Desk Inc — how do they compare? Incyte Corporation trades at $117.7 (market cap $23.11B), while Trade Desk Inc trades at $18.46 (market cap $8.76B). The key difference: Incyte Corporation is far larger — about 2.6× Trade Desk Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TTD | |
|---|---|---|
Market Cap | $23.11B | $8.76B |
Sector | Health | Technology |
52-Week High | $118.52 | $89.76 |
52-Week Low | $67.38 | $17.33 |
Enterprise Value | $19.13B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
The Trade Desk (TTD) trades at $18.68, down 76% year-to-date amid slowing revenue growth and executive turnover. Recent technical signals are bearish, with moving averages indicating selling pressure, while fundamentals show strong profitability with a 77.83% gross margin and 14.57% net margin. The company has beaten earnings estimates in two of the last three quarters but missed Q1 2026 expectations. Recent news highlights key executive appointments and a resolved dispute with Publicis Groupe.
Outlook: TTD faces headwinds from competitive pressure and growth deceleration, but current valuation at 21.13x P/E may attract value investors. Risks include market share loss to larger rivals and execution challenges. Analyst consensus price target of $25.23 suggests 35% upside potential, though sentiment remains divided with nearly equal buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
